ISCO and Absorption Sytems to Commercialize Stem Cell Derived Human Corneal Tissue for Drug Test
International Stem Cell Corporation (OTCBB:ISCO (www.internationalstemcell.com), the first company to perfect a method of creating human “parthenogenetic” stem cells from unfertilized eggs, has formed a partnership with Absorption Systems to utilize ISCO’s parthenogenetic stem cell-derived human corneal tissue to measure drug disposition, drug safety and drug-drug interactions. The collaboration between the companies is focused on using Absorption Systems’ know how in creating in vitro assay systems to develop a superior method of testing drugs that will also reduce the use of laborato...
Source: International Stem Cell Corporation - November 25, 2008 Category: Stem Cells Authors: internationalstemcell Tags: biotechnology science health medicine parthenogenesis stem cell Source Type: podcasts
ISCO and Absorption Sytems to Commercialize Stem Cell Derived Human Corneal Tissue for Drug Test
International Stem Cell Corporation (OTCBB:ISCO (www.internationalstemcell.com), the first company to perfect a method of creating human “parthenogenetic” stem cells from unfertilized eggs, has formed a partnership with Absorption Systems to utilize ISCO’s parthenogenetic stem cell-derived human corneal tissue to measure drug disposition, drug safety and drug-drug interactions. The collaboration between the companies is focused on using Absorption Systems’ know how in creating in vitro assay systems to develop a superior method of testing drugs that will also reduce the use of laboratory animals curren...
Source: International Stem Cell Corporation - November 25, 2008 Category: Stem Cells Authors: internationalstemcell Tags: biotechnology science health medicine parthenogenesis stem cell Source Type: podcasts
ISCO and Absorption Sytems to Commercialize Stem Cell Derived Human Corneal Tissue for Drug Test
International Stem Cell Corporation (OTCBB:ISCO (www.internationalstemcell.com), the first company to perfect a method of creating human “parthenogenetic” stem cells from unfertilized eggs, has formed a partnership with Absorption Systems to utilize ISCO’s parthenogenetic stem cell-derived human corneal tissue to measure drug disposition, drug safety and drug-drug interactions. The collaboration between the companies is focused on using Absorption Systems’ know how in creating in vitro assay systems to develop a superior method of testing drugs that will also reduce the use of laborato...
Source: International Stem Cell Corporation - November 25, 2008 Category: Stem Cells Authors: internationalstemcell Tags: biotechnology science health medicine parthenogenesis stem cell Source Type: podcasts
ISCO and Absorption Sytems to Commercialize Stem Cell Derived Human Corneal Tissue for Drug Test
International Stem Cell Corporation (OTCBB:ISCO (www.internationalstemcell.com), the first company to perfect a method of creating human “parthenogenetic” stem cells from unfertilized eggs, has formed a partnership with Absorption Systems to utilize ISCO’s parthenogenetic stem cell-derived human corneal tissue to measure drug disposition, drug safety and drug-drug interactions. The collaboration between the companies is focused on using Absorption Systems’ know how in creating in vitro assay systems to develop a superior method of testing drugs that will also reduce the use of laboratory animals curren...
Source: International Stem Cell Corporation - November 25, 2008 Category: Stem Cells Authors: internationalstemcell Tags: biotechnology science health medicine parthenogenesis stem cell Source Type: podcasts
JAMA: 2007-05-09, Vol. 297, No. 18, Author in the Room Audio Interview
Interview with Steven R. Steinhubl, MD, author of Aspirin Dose for the Prevention of Cardiovascular Disease. Summary Points: 1. While aspirin is generally a safe drug and extremely effective, with more than 50 million US adults taking it every day for cardiovascular disease prevention, even a very small incidence of adverse effects can have major implications. Consistent with this, one study found that the most common medication leading to an adverse event requiring hospitalization was aspirin for cardiovascular disease prevention. 2. In terms of preventing heart attacks, strokes, or cardiovascular deaths, no clinical tria...
Source: JAMA Author in the Room - July 13, 2007 Category: Journals (General) Authors: The JAMA Network Source Type: podcasts
JAMA: 2007-02-14, Vol. 297, No. 6, Author in the Room Audio Interview
Interview with Paul M. Ridker, MD, MPH, author of Development and Validation of Improved Algorithms for the Assessment of Global Cardiovascular Risk in Women: The Reynolds Risk Score. Summary Points: 1. Half of all heart attacks and strokes occur among those with normal cholesterol levels and 15-20% occur among those with no major risk factors at all. 2. The major breakthroughs in understanding cardiovascular disease over the past decade include insights about inflammation and genetics. Each of these can easily be ascertained with either a simple blood test (hsCRP for inflammation) or a simple question about parental histo...
Source: JAMA Author in the Room - April 13, 2007 Category: Journals (General) Authors: The JAMA Network Source Type: podcasts
" Gland Larceny " -- The Discovery Files
Most snakes are born with poisonous bites they use to ward off predators. But what's a non-poisonous snake to do? Researchers from Old Dominion University have identified some clever snakes that are relying on their diets for protection. They are " recycling " poison obtained from their diet of toxic frogs. (Source: The Discovery Files)
Source: The Discovery Files - February 9, 2007 Category: Science Authors: National Science Foundation Source Type: podcasts
